NRSN Relative Valuation
NRSN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NRSN is overvalued; if below, it's undervalued.
Historical Valuation
Neurosense Therapeutics Ltd (NRSN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.08. The fair price of Neurosense Therapeutics Ltd (NRSN) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：1.20
Fair
-3.91
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Neurosense Therapeutics Ltd. (NRSN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-3.05
EV/EBIT
Neurosense Therapeutics Ltd. (NRSN) has a current EV/EBIT of -3.05. The 5-year average EV/EBIT is -1.51. The thresholds are as follows: Strongly Undervalued below -3.62, Undervalued between -3.62 and -2.57, Fairly Valued between -0.45 and -2.57, Overvalued between -0.45 and 0.61, and Strongly Overvalued above 0.61. The current Forward EV/EBIT of -3.05 falls within the Undervalued range.
86.28
PS
Neurosense Therapeutics Ltd. (NRSN) has a current PS of 86.28. The 5-year average PS is 10.89. The thresholds are as follows: Strongly Undervalued below -56.87, Undervalued between -56.87 and -22.99, Fairly Valued between 44.76 and -22.99, Overvalued between 44.76 and 78.64, and Strongly Overvalued above 78.64. The current Forward PS of 86.28 falls within the Strongly Overvalued range.
-2.97
P/OCF
Neurosense Therapeutics Ltd. (NRSN) has a current P/OCF of -2.97. The 5-year average P/OCF is -0.99. The thresholds are as follows: Strongly Undervalued below -3.46, Undervalued between -3.46 and -2.22, Fairly Valued between 0.25 and -2.22, Overvalued between 0.25 and 1.49, and Strongly Overvalued above 1.49. The current Forward P/OCF of -2.97 falls within the Undervalued range.
-3.17
P/FCF
Neurosense Therapeutics Ltd. (NRSN) has a current P/FCF of -3.17. The 5-year average P/FCF is -1.13. The thresholds are as follows: Strongly Undervalued below -4.07, Undervalued between -4.07 and -2.60, Fairly Valued between 0.34 and -2.60, Overvalued between 0.34 and 1.82, and Strongly Overvalued above 1.82. The current Forward P/FCF of -3.17 falls within the Undervalued range.
Neurosense Therapeutics Ltd (NRSN) has a current Price-to-Book (P/B) ratio of -58.31. Compared to its 3-year average P/B ratio of -13.81 , the current P/B ratio is approximately 322.06% higher. Relative to its 5-year average P/B ratio of -9.79, the current P/B ratio is about 495.39% higher. Neurosense Therapeutics Ltd (NRSN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -26.84%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -22.03% , the current FCF yield is about -100.00% lower.
-56.89
P/B
Median3y
-13.81
Median5y
-9.79
-27.24
FCF Yield
Median3y
-26.84
Median5y
-22.03
Competitors Valuation Multiple
The average P/S ratio for NRSN's competitors is 0.00, providing a benchmark for relative valuation. Neurosense Therapeutics Ltd Corp (NRSN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NRSN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NRSN in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Neurosense Therapeutics Ltd (NRSN) currently overvalued or undervalued?
What is Neurosense Therapeutics Ltd (NRSN) fair value?
How does NRSN's valuation metrics compare to the industry average?
What is the current P/B ratio for Neurosense Therapeutics Ltd (NRSN) as of Dec 05 2025?
What is the current FCF Yield for Neurosense Therapeutics Ltd (NRSN) as of Dec 05 2025?
What is the current Forward P/E ratio for Neurosense Therapeutics Ltd (NRSN) as of Dec 05 2025?